For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Livagen (Lys-Glu-Asp-Ala, KEDA) is a Khavinson tetrapeptide designed from liver tissue peptide analysis. Its distinctive position in the family comes from two mechanistically specific findings: the 2002 Khavinson/Lezhava indexed study demonstrated chromatin deheterochromatinization in human lymphocytes from elderly donors (activation of ribosomal genes and decondensation of pericentromeric heterochromatin), and the 2003 Kost et al. study from the Mental Health Research Center in Moscow (an external institution) found that Livagen inhibits enkephalin-degrading enzymes in human serum with an IC50 of 20 micromolar, outperforming known peptidase inhibitors puromycin, leupeptin, and D-PAM. Neither study constitutes a clinical trial. No human efficacy data in any disease indication has been published.
The complete Livagen profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use